Xiao Ting, a director at Zenas BioPharma, Inc. (NASDAQ:ZBIO), has acquired 10,000 shares of the company's common stock, according to a recent filing with the Securities and Exchange Commission.

Christopher George uncovered a late 19th-century Civil War presentation sword in the attic of his historic family home, ...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...

Wolfe Research initiated coverage of Zenas BioPharma (ZBIO) with an Outperform rating and $19 price target After its IPO in September 2024, the stock traded down significantly along with many ...

Just a few months after raising $200 million in third-round financing, immunology specialist Zenas BioPharma has filed an initial public offering in the US seeking to add another $100 million to ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

Zenas BioPharma WALTHAM, Mass., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company ...

Zenas BioPharma announced advancements in the clinical development of obexelimab, a novel CD-19 x FcγRIIb inhibitor targeting B cell function, with key trial results expected in 2025. The Phase 2 ...